🇺🇸 FDA
Patent

US 11034667

Selective histone deacetylase inhibitors for the treatment of human disease

granted A61KA61K31/404A61K45/06

Quick answer

US patent 11034667 (Selective histone deacetylase inhibitors for the treatment of human disease) held by Shuttle Pharmaceuticals, Inc. expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Shuttle Pharmaceuticals, Inc.
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/404, A61K45/06, A61P, A61P35/00